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KESITOTOKSIKAN DAN MEKANISME KEMATIAN SEL TERHADAP TURUNAN 
SEL KANSER YANG DIELISITKAN OLEH EKSTRAK PHYSALIS MINIMA L. 
 
ABSTRAK 
 
Terapi herba semakin penting dalam perubatan alternatif untuk merawat kanser. Maka, 
tujuan kajian ini ialah untuk menentukan sitotoksisiti beberapa tumbuhan ubatan dan untuk 
menyelidiki mekanisma kematian sel yang dielisitkan oleh ekstrak yang paling poten dan 
fraksinya. Sejumlah 20 ekstrak daripada empat tumbuhan antikanser (Pereskia grandifolia, 
Vernonia cinerea, Elephantopus scaber dan Physalis minima) telah disaring terhadap tiga jenis 
turunan sel. Ekstrak kloroform Physalis minima telah menunjukkan kesan sitotosik yang paling 
tinggi terhadap sel kanser NCI-H23 (sel kanser peparu adenokarsinoma manusia), T-47D (sel 
kanser payudara manusia) dan Caov-3 (sel kanser ovari manusia), dengan nilai EC50 yang rendah 
iaitu 2.80μg/ml, 3.80μg/ml dan 5.10μg/ml masing-masing. Mekanisme kematian sel yang 
berlainan ditunjukkan oleh ekstrak tersebut terhadap jenis sel kanser yang berbeza. Didapati 
bahawa sel NCI-H23 dan T-47D yang diujikan dengan ekstrak tersebut menunjukkan tahap DNA 
fragmentasi yang lebih tinggi berbanding dengan sel Caov-3.  Pendedahan kepada ekstrak ini juga 
menghasilkan pengawalaturan pengekspresan mRNA c-myc, caspase-3 dan p53 yang signifikan 
terhadap semua jenis sel kanser. Penganalisaan ultrastruktur dan perwarnaan aneksin V juga 
mempamerkan kehadiran kematian sel secara apoptosis terancang di dalam semua sel kanser yang 
diperlakukan dengan ekstrak ini. Di samping itu, morfologi bukan apoptosis (vakuolar) juga 
diperhatikan dalam sebilangan sel Caov-3 dan sebahagian kecil sel NCI-H23 serta T-47D yang 
diperlakukan dengan ekstrak. Asai pengecualian tripan biru telah mengabaikan nekrosis sebagai 
punca utama kematian sel. Oleh itu, ekstrak kloroform Physalis minima mengelisitkan gabungan 
mekanisme kematian sel terancang pada sel Caov-3. dan mengaruhkan lebih banyak kematian sel 
secara apoptosis pada sel NCI-H23 dan T-47D. 
Penyisihan ekstrak kloroform Physalis minima telah menghasilkan 16 fraksi yang 
berbeza. Hanya sebilangan fraksi daripada ekstrak kloroform ini menunjukkan aktiviti sitotosik 
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terhadap sel T-47D, dengan fraksi F11 merupakan fraksi yang paling poten, dengan nilai EC50 
yang paling rendah (3.60μg/ml). Fraksi F10, F11 dan F13 mempamerkan DNA fragmentasi yang 
tipikal berkaitan dengan apoptosis dalam sel T-47D. Asai pengecualian tripan biru menunjukkan 
bahawa nekrosis tidak memainkan peranan utama dalam mengaruhkan kematian sel T-47D oleh 
fraksi-fraksi tersebut. Kajian lanjutan telah menunjukkan bahawa fraksi F11 dan ekstrak 
kloroform paling banyak mengaruh kematian sel secara apoptosis dalam sel T-47D, berdasarkan 
perwarnaan kebanyakan sel dengan aneksin V yang lemah dan pengawalaturan pengekspresan 
mRNA c-myc, caspase-3 dan p53 secara signifikan. Selain itu, sebilangan sel T-47D yang 
diperlakukan dengan fraksi F10 dan F13 pula diwarnakan oleh kedua-dua aneksin V serta 
propidium iodida, yang seterusnya mencadangkan kewujudan gabungan mekanisma kematian sel 
berprogram. Pisalin B, F dan K telah dikenalpastikan sebagai sebatian utama di dalam fraksi F11. 
Kombinasi sebatian pisalin ini dalam ekstrak dan fraksi mungkin bertanggungjawab terhadap 
aktiviti sitotosik dan kematian sel T-47D secara terancang. Penemuan ini patut diteruskan 
penyelidikannya agar Physalis minima dapat digunakan dalam terapi kanser kerana kesan 
antikansernya yang melibatkan apoptosis dan autofagi terhadap turunan sel kanser. 
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CYTOTOXICITY AND CELL DEATH MECHANISMS AGAINST CANCER CELL 
LINES ELICITED BY THE EXTRACTS OF PHYSALIS MINIMA L. 
  
ABSTRACT 
 
Herbal therapy is fast becoming an important alternative medicine for cancer treatment. 
Therefore, the aims of this study were to determine cytotoxicity of some medicinal herbs and to 
investigate cell death mechanism elicited by the most potent extract as well as its fractions. A total 
of 20 extracts form four anticancer plants (Pereskia grandifolia, Vernonia cinerea, Elephantopus 
scaber and Physalis minima) were screened against three different cancer cell lines. Physalis 
minima (Leletup-direct translation from Malay) chloroform extract was shown to exhibit 
remarkable cytotoxic effects on NCI-H23 (human lung adenocarcinoma), T-47D (human breast 
carcinoma) and Caov-3 (human ovarian carcinoma) cell lines, with EC50 derived at 2.80μg/ml, 
3.80μg/ml and 5.10μg/ml, respectively. Different cell death mechanisms exerted by this extract on 
different cell lines. It was found that DNA fragmentation level of the extract-treated NCI-H23 and 
T-47D cells was higher than Caov-3 cells. Acute exposure to the extract produced a significant 
regulation of c-myc, caspase-3 and p53 mRNA expression in all cell lines. Ultrastructural analysis 
and annexin V staining also demonstrated the presence of apoptotic programmed cell death in the 
extract-treated cell lines. Furthermore, the appearance of non-apoptotic (vacuolar) morphology 
was observed in some treated Caov-3 cells and in minority of treated NCI-H23 and T-47D cells. 
Trypan blue exclusion assay ruled out necrosis as the main cause of death. Thus, cell death 
mechanism elicited by the Physalis minima chloroform extract appeared to be a mixture of 
programmed cell death in Caov-3 cells and a major apoptotic cell death in both NCI-H23 and T-
47D cells.  
Fractionation of Physalis minima chloroform extract revealed 16 different fractions. Only 
some of the fractions exhibited cytotoxic activities against T-47D cells, with F11 being the most 
potent, exhibiting the lowest EC50 (3.60μg/ml). Fractions F10, F11 and F13 exhibited typical 
DNA fragmentation associated with apoptosis in T-47D cells. Trypan blue exclusion assay 
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demonstrated that necrosis did not play a major role in eliciting T-47D cell death of these 
fractions. Further investigations revealed both fraction F11 and chloroform extract induced major 
apoptotic cell death in T-47D cells, which was based on majority of weakly diffused annexin V 
stained cells and significant regulation of c-myc, caspase-3 and p53 mRNA expression levels. 
Meanwhile, a considerable number of T-47D cells treated with fractions F10 and F13 were 
stained with annexin V and propidium iodide, which further suggested the presence of a mixture 
programmed cell death. Physalins B, F and K were identified as major constituents in fraction 
F11. Combination of these physalin compounds in the extract and fraction may have contributed 
to the cytotoxic activities and programmed cell death of T-47D cells. These findings warrant 
further research on Physalis minima plant for use in cancer therapy due to its apoptosis- and 
autophagy-dependent anticancer effect on cancer cell lines. 
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1.1  Complementary and alternative medicine (CAM) 
Recently, a greater emphasis has been given towards the use of herbs as 
complementary and alternative medicine (CAM) that deals with cancer management (Powell 
et al., 2003). CAM is a generic term for a vast range of modalities and practices that are 
outside the mainstream of conventional medicine (Kelly, 2004; Verhoef et al., 2005). These 
therapies are spiritual healing, homoeopathy, herbal remedies, megavitamins, acupuncture, 
relaxation, meditation and psychologic methods (Fisher & Ward, 1994; Eisenberg et al., 
1998; Pud et al., 2005). Herbal medicines are among the most widely used form of CAM (de 
Smet, 2002; Barnes, 2003; Algier et al., 2005). The increasing of positive view in herbal 
medicines compared with conventional therapies, largely because they are perceived as being 
“natural” and “safe” (Pirmohamed, 2003). A large number of breast and ovarian cancer 
patients have taken herbal therapies as complementary medicines concurrently with 
conventional treatments (Lee et al., 2000; Powell et al., 2002). The fact that they believe 
herbal treatments are able to boost their immune system, prolong life, relieve symptoms and 
ameliorate on the desirable side effects of Western therapies (Richardson et al., 2000). 
Among alternative therapies, traditional Chinese medicine (TCM) is probably the 
best established and codified (Lim et al., 2005), dating back several thousand years (Fen et 
al., 2001). The origins and development of TCM are based on accumulation of daily 
experience and expert knowledge in herbal medicines (Chang, 1992). In TCM, the ying-yang 
is employed to explain the pathology changes in the human body and to guide the clinical 
diagnosis, and treatment (Cheng, 2000). Herbal medicines are used to restore or maintain 
balance between these elements and to grant vital energy (qi) in human body, which has both 
yin and yang aspects (Borrel, 2001; Fakim, 2006). 
Guided by therapeutic experience of TCM, a number of antineoplastic drugs have 
been found (Han, 1988; Han, 1994; Cai et al., 2004). Indirubin from Indigofera tinctoria 
(Hoessel et al., 1999; Bradbury, 2005) and homoharringtonine from Cephalofaxus 
hainanesis (Luo et al., 2004; Mai & Lin, 2005) have exhibited significant antileukemia 
activities. Experimental therapeutic studies indicated that irisquinone from Iris pailasti (Li et 
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al., 1981) and 10-hydroxy comptothecin from Camptothera accuminata (Li et al., 2004) 
produced definite activities on rodent tumors. Daidzen (Jing & Han, 1993) and ginsenoside 
(Ota et al., 1997; Helms, 2004) have shown to be effective in inducing cell differentiation in 
leukemia cells (HL-60) and melanoma cells (B-16), respectively.  
Of note, TCM has been integrated with Ayurvedic herbs (traditional Indian 
medicines) in CAM for suppressing various tumors (Tillotson et al., 2001; Patwardhan et al., 
2005). Indian traditional medicine is mainly based on various system including Ayurveda, 
Siddha, Unani, Naturaphaty and homocophaty (Satyavati, 1990). These traditional systems 
have provided a great deal of information on the folklore practices and traditional aspect of 
natural products (Mukherjee et al., 1998). The Ayurvedic therapies have a unique principal, 
which includes pathogenesis of tumors, therapeutic methodologies and combination of 
herbal ingredients (Premalatha & Rajgopal, 2005). Plant alkaloids are the primary active 
ingredients of Ayurvedic medicines (Borchardt, 2003). Other pharmacologically active 
compounds are being found in Ayurvedic plants, such as polyphenols, tannins and 
triterpenoids, which produce potential therapeutic effect in cancer remedies (Kaur et al., 
2005). 
Besides Ayurveda, the Malay folk medicinal plants are also being used as an 
alternative approach for the cancer treatment (Chen, 1981). The local traditional Malay 
medicine is actually found on the basic principle of Indonesian traditional medicine and has 
been modified to suit the current needs (Zakaria & Mohamad, 1994). Herbal decoctions 
consisting of multiple herbs each possessing tremendous potential for a cancer cure are 
commonly being used in Malay traditional medicine (Ong, 2004). Scientific studies have 
shown that several of Malay traditional vegetables (ulam) used as herbal medicines are 
reported to be cytotoxic against various types of cancer cells (Mohamed et al., 2005). A 
finding has demonstrated that several of Malay traditional plants contain high bioactive 
compounds, which are potentially be used for cancer therapy and other diseases (Rao, 2001).  
As for all local traditional medical systems, herbal medicines have extensively been 
used as an alternative approach for preventing cancer. Therefore, the experience of these 
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traditional medicines could provide a potential resource to explore chemopreventive herbs 
and may also lead to the isolation of novel anticancer compounds. 
 
1.2  Anticancer Agents 
 
 Written records of the use of pure natural drugs in cancer chemotherapy date back 
about 30 years. A number of anticancer agents have been discovered by screening natural 
products from plants, microorganisms and marine organisms (Cragg & Newman, 1999). 
Anticancer drug development has been oriented towards seeking target-specific or target-
selective compounds using a screen composed of human tumor cell lines organized by tissue 
types (Cragg & Suffness, 1988). The new targets should be preferentially evaluated as sites 
for anticancer drug (Verweij, 1996). The result from the interaction of drugs with cellular 
targets, mechanism of damage repair and gene expressed within tumor and non-tumor cells 
are considered the cellular responses to anticancer agents (Danesi et al., 2001). With the 
technological advancement in molecular biology and genomics, majority of drug discovery 
research is currently based on the molecular approach (Harvey, 1999).   
 
1.2.1  Plant derived anticancer agents 
Despite many research advancements in cancer chemotherapy, plant natural products 
still make an enormous contribution to drug discovery (Hamburger & Hostettmann, 1991; 
Lee, 1999). There are approximately 60 available cancer chemotherapeutic drugs that were 
derived from plants (Kinghorn et al., 1999). Several plant derived agents are currently 
having great significance in cancer treatment. One of the best known classes of these agents 
is the dimeric Vinca alkaloid, which was isolated from the periwinkle Catharanthus roseus 
(Noble, 1990). The Vinca alkaloids (vinblastine and vincristine) are useful primarily in the 
treatment of Hodgkin’s disease and childhood leukemia, respectively (Sneden, 1984; 
Hamburger and Hostettmann, 1991). Another two new clinically approved semisynthetic 
Vinca alkaloid derivatives, vindesine and vinorelbine are now  widely used and licensed for 
the treatment of non-small cell lung cancer, metastatic breast cancer and ovarian cancer 
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(Ashizawa et al., 1993; Leveque et al., 1993; Romero et al., 1994; Kruczynski & Hill, 2001). 
These compounds work by interfering microtubule polymerization and subsequently arrest 
mitosis in the metaphase (Himes, 1991; Jordan et al., 1991; Panda et al., 1996; Wilson et al., 
1999). Epipodophyllotoxins, etoposide and teniposide are anticancer drug derived from the 
mandrake plant Podophyllum peltatum (Imbert, 1998; Hande, 1992; Zhang et al., 2005). 
These agents are topoisomerase II inhibitors, which prevent the cleavage and resealing of 
DNA strands (Ross et al., 1984; Giaccone, 1995; Gordaliza et al., 2001). Etoposide has 
produced high cure rates in testicular cancer and lung cancer, while teniposide is mainly used 
to treat leukemia, lymphoma and Kaposi’s sarcoma (Selvin et al., 1989; Johnson et al., 
1997a; Gordaliza et al., 2000).   
Other prominent antimicrotubule agents, such as paclitaxel and docetaxel, arise from 
the taxol extracts of the pacific yew Taxus brevifolia (Panvichian et al., 1998; Jordan, 2002; 
Marchetti et al., 2002; Montera et al., 2005). They are effectively used to treat lung, breast 
and ovarian carcinomas (Kingston, 1994; Cortes & Pazdur, 1995; Crown & O’Leary, 2000; 
Perez et al., 2001). In addition, the camptothecin derivatives, irinotecan and topotecan, have 
exhibited impressive antitumor activity against colorectal and ovarian cancers, respectively 
(Giovanella et al., 1989; Jonsson et al., 2000; Oguma, 2001). These compounds were 
obtained from the stembark of Nyssacca (Camptotheca accuminata) and act by inhibiting 
topoisomerase I (Slichenmyer et al., 1993; Johnson et al., 1997b; Liu et al., 2000; Wu, 
2003). 
 
1.2.2 Microbe derived anticancer agents 
 Antitumor antibiotics are among the best and important cancer chemotherapeutic 
agents with the widest spectrum of activity in human neoplasm (Cragg et al., 1997). The 
majority of these agents are originally isolated from fermentation products of Streptomyces 
peucetus (Spiegel, 1984). These microbially derived agents are topoisomerase I and II 
inhibitors that intercalate between paired bases of the DNA and thereby have inhibitory 
effects on DNA or RNA synthesis (Bachur et al., 1992; Sinha, 1995; Sutter et al., 1997; 
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Binaschi et al., 2000). Mitomycin (Peterson et al., 1995; Paz et al., 1999) and bleomycin 
(Hay et al, 1991; Scarpato et al., 1998) are known to cause DNA damage via the formation 
of DNA cross-links and the production of oxygen free radicals, respectively. Both drugs 
have been used in the treatment of head and neck squamous cell carcinoma (Haffy et al., 
1997), Hodgkin lymphomas, testicular carcinoma (Mir et al., 1996; Azambuja et al., 2005) 
and colon cancer (Pan & Gonzalez, 1997; Spanswick et al., 1998). 
The anthracycline antibiotics, doxorubin, daunomycin and adriamycin are primarily 
employed in clinical antineoplastic drugs (Blum & Carter, 1974; Arcamone, 1980; Westwell, 
2002). Although these agents are active against a variety of solid tumor and haematologic 
malignancies, their clinical use is limited by tumor resistance and toxicity to healthy tissue 
(Hortobagyi, 1997; Husseini et al., 2002; Lin et al., 2005). Subsequently, new anthracycline 
anticancer agents such as ansamycin (Schulte & Neckers, 1998), amrubicin (Ogawa, 1999), 
esorubicin, epirubicin and idarubicin (Weiss, 1992; Arcamone et al., 1997; Kim et al., 1999) 
have been synthesized to increase the antitumor activity and to decrease the undesirable side 
effects. In fact, almost all clinically active anthracyclines are anthraquinones (Hande, 1998). 
Among a series of anthracenediones, mitoxantrone is the most active and has demonstrated a 
spectrum of antitumor activity similar to the anthracyclines, but with less cardiotoxicity 
(Posner et al., 1985; Faulds et al., 1991).         
 
1.2.3 Marine derived anticancer agents 
 In recent years, promising compounds are being tapped from the world’s oceans. 
Several new compounds derived from marine organisms have entered preclinical and clinical 
evaluation as anticancer candidates (Cooper, 2004). For example, didemnin B, aplidine and 
ecteinascidine 743 are derived from tunicates (Schwartsmann et al., 2001). Didemnin B is a 
cyclic desipeptide isolated from the tunicate Trididemnum solidum. It has exhibited potent 
preclinical antitumor activity. However, its clinical use was hindered by cardiotoxicity and 
neuromuscular toxicity (Shin et al., 1991; Rinehart, 2000). Aplidine, a related desipeptide 
was subsequently isolated from the Mediterranean tunicate Aplidium albicans. Several 
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studies indicated that aplidine appears to be more potent antitumor activity than didemnin B 
and lacks severe secondary effects in preclinical models (Urdiales et al., 1996; Rinehart, 
2000). 
 Numerous ecteinascidins have been derived from the marine tunicate Ecteinascidia 
turbinata. Preclinical studies have demonstrated that ecteinascidin 743 is active against a 
variety of solid tumor cell lines and has promising activity in phase I and phase II clinical 
trials (Minuzzo et al., 2000; Damia et al., 2001; Erba et al., 2001). Other agents originating 
from marine sources are dolastatin and bryostatin, which have currently entered phase I and 
II clinical trials (Pitot et al., 1999; Poncet, 1999; Pagliaro et al., 2000). These compounds 
have shown activity against malignant melanoma and colorectal cancer, respectively (Pathak 
et al., 1998; Propper et al., 1998; Zonder et al., 2001).        
 
1.2.4 Metal complexes and hormonal agents 
 The platinum compounds, cisplatin and carboplatin, are two of the most commonly 
used anticancer drugs in treatment of solid tumors including lung, ovarian, cervix, head and 
neck cancers (Petering et al., 1984). Of note, the platinum-based chemotherapy has 
administered in combination with other anticancer agents (such as paclitaxel, etoposide, 
vincristine, vinblastine and bleomycin) for significant regimens in testicular, ovarian and 
lung carcinomas (Williams et al., 1987; Eisenhauer & Vermorken, 1998; Rogers et al., 2002; 
Reck et al., 2003). These platinum compounds act by forming cross linking of DNA strands 
and inhibiting of DNA replication (Spiegel, 1984; Lan & Ng, 2002). Nedaplatin and 
platinum (II) complexes are new platinum analogs which recently have pronounced 
preclinical antitumor activities against solid tumors, virtual low rate of nephrotoxicity and 
relatively less neurotoxicity (Alberts et al., 1997; Young et al., 2002). Another new 
generation of platinum agent, oxaliplatin, was reported to have poor activity as a single agent 
against breast cancer, but interesting results in combination regimens (Awada et al., 2003).  
 Hormonal therapy is a systemic therapeutic approach in the management of 
postmenopausal women with metastatic breast cancer (Dellapasqua & Gertsch, 2005). 
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Tamoxifene, the first selective estrogen receptor modulator (SERM), was primarily 
synthesized as a drug against hormone responsive breast cancer (Mocanu & Harrison, 2004). 
This nonsteroidal antiestrogen has been used as adjuvant in the treatment of early stage 
breast cancer for over 20 years (Awada et al., 2003). One known mechanism is that the 
tamoxifene molecule competes with estrogen for binding to estrogen receptors, thus the 
effect of estrogen to promote the growth of breast cancer cells is diminished (Rong et al., 
2005). Tamoxifene is also found to be effective in the treatment of hormone non-responsive 
breast cancers that do not express estrogen receptors (Salami & Tehrani, 2003). In addition 
to breast cancer, tamoxifene has been used to treat other cancers such as hepatocellular 
carcinoma (Simonetti et al., 1997), ovarian cancer (Trope & Kaern, 2000) and prostate 
cancer (Bergan et al., 1999). However, tamoxifene’s uterine adverse effects pushed the 
ongoing research to develop new agents with higher affinity for the estrogen receptor (Neven 
& Vergota, 2001). 
Following tamoxifene, a number of new antiestrogens have been developed in 
attempt to increase its efficacy and reduce the partial agonist properties. The first generation 
SERMs, idoxifene (Nuttall et al., 2000), toremifene (Holli, 2002; Chen et al., 2002) and 
droloxifene (Hasmann et al., 1994), have shown minimal activities in tamoxifene-resistant 
diseases (Robertson et al., 2005). Both have stimulatory effects on the uterus (Gonzalez et 
al., 1998; Morello et al., 2002; Harvey et al., 2005). Efficacy results for second generation 
SERMs such as raloxifene (Gasco et al., 2005) and arzoxifene (Freddie et al., 2004) are not 
high, although raloxifene exhibits promise in the chemoprevention of breast cancer (Neven 
et al., 2005). Consequently, there is a need for new endocrine therapeutic approaches for 
breast cancer, especially for use in disease that is resistant to tamoxifene. Fulvestrant is a 
new type of steroidal estrogen receptor antagonist with no agonist effects (Robertson, 2004). 
Fulvestrant has a unique mechanism of action, which binds, blocks and leads to estrogen 
receptor degradation (Steger et al., 2005). This agent exerts high efficacy result compared 
with the SERMs palliative approach in the treatment of advanced breast cancer (Howell & 
Abram, 2005). Furthermore, the newer aromatase inhibitors, exemestane, anastrozole and 
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letrozole have demonstrated greater efficacy than tamoxifene as first line treatments for 
metastatic breast cancer with significantly better toxicity profiles (Coombes et al., 2003; 
Dowsett & Haynes, 2003). 
 
1.3 Programmed cell death  
Cell death is a fundamental process in normal development, tissue homeostasis and 
integrity of multicellular organisms (Hakem & Harrington, 2005). The tight regulation of 
both cell proliferation and cell death is required to generate the proper numbers and types of 
cells during differentiation and to maintain this balance in the mature animal (Ellis et al., 
1991). Unwanted cells are eliminated during metamorphosis, embryogenesis, pathogenesis 
and tissue turnover (Hakem & Harrington, 2005). In vertebrates, naturally-occurring cell 
deaths have been extensively observed in almost all tissue (Cole et al., 1993), in the nervous 
system (Becker & Bonni, 2004) and in the immune system (Krammer, 2000). These cell 
deaths, which involve a genetically programmed process of the cell to promote a cascade of 
cell suicide mechanism in response to specific signals, are known as programmed cell death 
(Gorski & Marra, 2002).  
There are numerous cell death mechanisms that are tissue-specific and cell type-
specific (le Blanc, 2003). Typically, programmed cell death is regulated by a variety of 
extracellular and intracellular signals which is governed by the environment of the cell (le 
Blanc, 2003). Under critical physiologic conditions, programmed cell death is initiated in 
specific cell types by endogenous tissue-specific agents and exogenous cell-damaging agents 
(Neuman et al., 2002). Various exogenous activations of programmed cell death, physical 
agents (such as, radiation, physical trauma, cold shock and chemotherapeutic drugs) and 
infectious agents (such as viruses and bacterial toxin) act on most types of cells (Duckett et 
al., 1998). Internal imbalances can also trigger apoptosis, including growth factors 
withdrawal, treatment with glucocorticoids, ablation of trophic hormone and loss of matrix 
attachment (Caron-Leslie et al., 1991; Neuman et al., 2002).  
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Programmed cell death plays an essential role in normal development, especially in 
the epigenetic self-organization process, in sexual dimorphism (the counterpart of certain sex 
type) and in morphogenesis (the sculpting of the form of embryos) (Saran, 2000). 
Programmed cell death is crucial in the adult, by allowing tissues homeostasis primary 
defense against viral infections (Fan et al., 1998) and the regulation of aging process (Monti 
et al., 1992). Programmed cell death also functions to eliminate cells that are produced in 
excess, abnormal, misplaced, non-functional or potentially dangerous to the organism 
(Jacobson et al., 1997). Conversely, programmed cell death deregulation has been proposed 
to participate in the pathogenesis of several diseases, including tumorigenesis, autoimmunity, 
neurodegenerative disorders and infectious diseases (Reed, 1999).  
The term apoptosis usually refers to a morphological type often observed in 
programmed cell death. It presents the defining characteristics of a cell death program, 
including cell shrinkage, membrane blebbing, nuclear fragmentation and segmentation of the 
cell into apoptotic bodies (Ameisen, 2002). Indeed, many research groups began to consider 
programmed cell death and apoptosis as a single entity (Melino, 2002). However, recent 
studies have proven that the concept of programmed cell death as a sequence of events are 
based on cellular metabolism, but not necessarily those that led to the morphology of 
apoptosis (Sloviter, 2002). In other words, some programmed cell death may not involve the 
mechanism of apoptosis. For this reason, the term ‘apoptosis’ should never be considered 
synonymous with programmed cell death (Guimaraes & Linden, 2004). 
 
1.3.1 Programmed cell death in inverterbrate 
The molecules that participate in the basic steps of programmed cell death are best 
defined through genetic studies in the nematode Caenorhabditis elegans (Horvitz, 2003). 
Among the 1090 somatic cells generated during Caenorhabditis elegans hermaphrodite 
development, 131 of its cells undergo programmed cell death (Conradt & Horvitz, 1998). 
Four essential genes have been identified ced-3, ced-4, ced-9 and egl-1 that regulate the 
commitment step that decides the ultimate life or death fate of cell (Shaham et al., 1999). 
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Most significantly, ced-3 and ced-4 are necessary for the activation of cell death, while ced-9 
inhibits it (Han et al., 1998). Ced-9 is a repressor of cell death, which binds to Ced-4, 
prevents it from activating Ced-3 (Hugunin et al., 1996). Recent studies reported that 
Caenorhabditis elegans contains an antagonist of Ced-9 called Egl-1, that by binding to it 
and prevents it from suppressing cell death, thus functioning as a transdominent inhibitor of 
Ced-9 (Conradt & Horvitz, 1998). Indeed, the completion of the ‘death program’ will depend 
on the interactions between each of these four proteins and their respective expression level 
is regulated by cell signaling during development (Seydoux & Priess, 2005). Subsequently, 
the dead cells are immediately engulfed and degraded by neighboring cells (Horvitz, 2003). 
Seven genes (ced-1, -2, -5, -6, -7, -8 and -10) are involved in initiation of phagocytosis while 
gene nuc-1 is involved in degradation of pycknotic DNA of dead cells (Wu et al., 2000; 
Seydoux & Priess, 2005).  
In Drosophila melanogaster, large numbers of cells die during metamorphosis as 
well as embryonic development exhibited the morphological characteristics of apoptosis 
(White et al., 1994). Three genes, rpr (reaper), hid (head involution defective) and grim, have 
been shown to activate caspase activity in Drosophila (Grether et al., 1995; Vucic et al., 
1998). By contrast, identification of Diap1 (inhibitor of apoptosis protein - IAP), has shown 
to inhibit caspase activity and to suppress apoptosis when overexpressed (Hay et al., 1995).  
The observation on the cell death in Caenorhabditis elegans and Drosophila 
melanogaster contributed more to the understanding of the molecular mechanism of 
programmed cell death (Kanuka et al., 1999). In fact, the genetic basis of these systems has 
an added advantage over the other systems and encouraged researchers to search for the 
functional homologues of these genes in mammals (Hale et al., 1996). 
 
1.3.2 Mammalian homologues of programmed cell death genes from Caenorhabditis 
elegans  
Many homologues are new emerging between genes during invertebrates 
development and genes activation in mammalian tissues and tumors (Yuan & Horvitz, 2004). 
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Thus, the nematode Caenorhabditis elegans and the fruit fly Drosophila melanogaster 
appear to share with mammals at least part of a common pathway to programmed cell death 
(Steller, 1995; Haining et al., 1999). Molecular analysis revealed that the cell death protein 
encoded by ced-3 showed significant similarity to mammalian protein, namely interleukin-
1β-converting enzyme (ICE) (Yuan & Horvitz, 2004). In fact, ICE protease has played a 
crucial role in apoptotic regulation of mammalian cells (Duan et al., 1996). A single 
mammalian homolog of Ced-4 has been identified thus far, termed apoptotic protease 
activating factor (Apaf) (Zou et al., 1997). However, the human Apaf-1 is structurally more 
complex than the nematode Ced-4 (Hu et al., 1998). Similarly, the Ced-4 promotes apoptosis 
by binding to the Ced-3, while the Apaf-1 induces mammalian apoptosis by activating the 
proteases such as Caspase-3 (Izban et al., 1999).  
The gene product of ced-9 is involved in the tight regulation of ced-3 and ced-4 
genes (Yan et al., 2005). ced-9 itself encodes for a 280 amino acid protein showing 23% 
homolog with mammalian bcl-2 proto-oncogene product (Desoize, 1994). The bcl-2 family 
consists of around 20 gene products, including antiapoptotic proteins (Bcl-2, Bcl-XL, Bcl-W, 
Mcl-1, Bcl-G and A1) and proapoptotic proteins (Bax, Bak, Bcl-XS, Bid, Bad, Bik, Blk, and 
Bim) (Maser et al., 2000). The family members have four conserved Bcl-2 homology (BH) 
domains: BH1, BH2, BH3 and BH4 (Wang et al., 1999a). The BH3 domain is an important 
component in inducing apoptosis, while the BH4 domain is involved in the anti apoptotic 
functions (Zhang et al., 2000). 
Both BH1 and BH2 domains show ion channel activity for regulating the release of 
cytochrome C from mitochondria (Yang et al., 1997). The release of cytochrome C is central 
in turning apoptosis on or off and is determined by the ratio of proapoptotic to antiapoptotic 
proteins (Kuwana et al., 2002). Some of the bcl-2 family members can share the capacity to 
homodimerize and to neutralize each others through heterodimerization (Cohen-Saidon et 
al., 2003). Thus, the susceptibility of cells to undergo apoptosis is determined by the way 
dimerize protein combine and mix and concentration of individual proteins (Oltvai et al., 
1993). Bcl-2 appears to be localized to the outer mitochondria membranes, nuclear, and 
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endoplasmic reticulum (Heiden & Thompson, 1999). Recent studies have associated 
commitment to apoptotic cell death with loss of mitochondrial membrane potential and have 
indicated that the membrane potential gradient can be maintained by Bcl-2 overexpression 
(Martinou & Green, 2001). Overexpression of Bcl-2 is associated with drug resistance in the 
chemotherapy (Wilson et al., 1997). Conversely, the down-regulation of Bcl-2 by antisense 
oligonucleotides enhances drug sensitivity in the promotion of apoptosis (Sawada et al., 
2000). Thus, the effectiveness of the level of chemotherapy might depend on the level of 
Bcl-2 expression and the interaction with proapoptotic genes in overcoming cellular drug 
resistance in cancer cells (Cory & Adams, 2002; Davis et al., 2003). 
 
1.4 Functions and types of cell death 
Physiological cell death is a widespread phenomenon in the development of 
multicellular organisms (Clarke, 1990). Cell death is typically discussed dichotomously as 
either necrosis (accidental cell death) or apoptosis (programmed cell death) (Farber, 1994; 
Raza et al., 2002). Although programmed cell death has often been equated with apoptosis, it 
is well known that nonapoptotic form of programmed cell death also exists (Bursch et al., 
2000; Kroemer et al., 2009). These nonapoptotic cells use different pathways for active self-
destruction as reflected by different morphological and biochemical events (Bursch et al., 
2000). Both apoptotic and non-apoptotic cell death have been defined in normal physiology 
and during tumorigenesis and these could potentially be contributed to the deletion of 
cancerous cells (Castro-Obregon et al., 2004).  
 
1.4.1 Apoptosis 
The term apoptosis was proposed by Kerr and his colleagues in 1972. It has been 
used to describe a specific morphological pattern of cell death observed as cells that were 
eliminated during embryonic development, neurode generation and normal physiological 
processes and pathological conditions (Kerr et al., 1972). Notably, apoptosis in the classical 
Greek word meaning ‘a falling off’, as leaves from a tree (Bowen et al., 1998; Elmore, 
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2007). The word connotes a controlled physiologic process of removing individual 
component of an organism without destruction to the organism (Bowen et al., 1998; Elmore, 
2007). Apoptosis is characterized by a series of typical morphological changes, including 
cell shrinkage, nuclear condensation, chromatin margination, membrane blebbing and 
convolution of the nuclear and cytoplasmic membranes followed by the formation of 
apoptosis bodies (Kroemer et al., 2009). The cytoplasmic organelles remain well preserved 
(Leist & Nicotera, 1998). These apoptotic bodies were then rapidly engulfed by 
neighbouring cells with little or no inflammatory response occurring (Wiegand et al., 
2001).The biochemical event of apoptosis is the cleavage of chromatin into nucleosomal 
fragments that are multiples of units comprising 180-200 base pairs (Arends et al., 1990). As 
a genetically programmed form of cell death, apoptosis is mediated by a family of cysteine 
proteases known as the caspase (Thornberry & Lazebnik, 1998). The activation of caspase is 
essential for the execution of apoptotic chromatin degradation (Cohen, 1997). Another 
important characteristic of apoptosis is externalization of cell surface phosphatidylserine, 
which can be recognized by phagocytes as a signal for engulfment (Koopman et al., 1994). If 
the body is not phagocytosed, it may undergo degradation which resembles necrosis in a 
process called secondary necrosis (Bowen et al., 1998). 
 
1.4.2 Autophagy 
Interest in non-apoptotic forms of programmed cell death has grown recently, 
especially autophagic cell death or termed as type II cell death. It plays a major role in the 
degradation of cellular components within the dying cell in autophagic vacuoles (Baehrecke, 
2003; Degenhardt et al., 2006). Autophagy has been extensively described to occur in 
Drosophila salivary gland (Myohara, 2004) and vertebrates including humans (Schweichel 
& Merker, 1973). It is usually associated with the elimination of large secretory cells during 
adjustment of sexual organs and ancillary tissues to seasonal reproduction. In yeast cells, 
autophagy cell death is induced under various nutrient starvation condition (Abeliovich & 
Klionsky, 2001). As to pathophysiology, autophagy has been associated with models of 
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tumorigenesis (Hermann et al., 1995) and human neurological disease (Liberski et al., 2004). 
Autophagy can be derived into macroautophagy and microautophagy, which differ in their 
mechanism of vacuole formation and delivery of material (van Doorn & Woltering, 2005). 
Briefly, the macroautophagy pathway in mammalian cells begins with the sequestration of 
larger portions in the cytoplasm to form an early autophagosomes (Devrim & Adi, 2004). 
The early autophagosome is generally considered to derive from the endoplasmic reticulum 
and also has been suggested to originate from the post-Golgi membranes (Denis & Codogno, 
2003). On the contrary, microautophagy operates by invaginating a portion of pre-existing 
vacuolar membrane to engulf cytosol or organelles (van Doorn & Woltering, 2005). The 
sequestration process is under the control of GTPase, phosphatidylinositol kinase and 
involves ubiqitin conjugation system (Denis & Codogno, 2003). All autophagosomes 
eventually fuse with lysosomes, thereby, the final degradation of the sequestered cytoplasmic 
material is triggered (Devrim & Adi, 2004). Genetic screens in yeast and Drosophila have 
led to the discovery of APG (autophagy) gene and AUT (autophagocytosis) gene that 
encoded protein need for the induction and regulation of autophagy process (Abelivich & 
Klionsky, 2001; Baehrecke, 2003). In addition, beclin 1 is the mammalian functional 
homolog of yeast apg-6 gene that is involved in the early steps of autophagic vesicle 
formation (Huettenbrenner et al., 2003). This is the first reported autophagic gene in 
mammalian and has the properties of a tumor suppressor gene (Liang et al., 1999; Yang & 
Peng, 2008). 
 
1.4.3 Non-lysosomal and cytoplasmic cell death 
The third morphological type of programmed cell death is often seen in mature 
neurons as a form of atrophy and may be induced by withdrawing nerve growth factor 
(NGF) (Amin et al., 2000). The type III cell death is distinguished from the type II cell by its 
lack of lysosomal involvement (Liberski et al., 2004; van Doorn & Woltering, 2005). 
Instead, this cell death is characterized by swelling of intracellular organelles, following by 
the formation of empty spaces in the cytoplasm, which eventually merge with each other 
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(Lee & Baehrecke, 2001). As noted by Clarke (1990), the type III cell death has been further 
subdivided into types 3A (non-lysosomal cell death) and 3B (cytoplasmic cell death). 
Although both types of cell death (3A and 3B) exhibit dilation of intracellular organelles and 
formation of non-lysosomal vacuoles, they differ in the apparent manner of cell degradation 
(Clarke, 1990). For non-lysosomal cell death, the cytoplasmic membrane of a cell is 
degraded with nuclear vacuolation in the late stage (Hirai & Harada, 2004). Meanwhile, the 
nuclear of cytoplasmic degradation exhibits granular chromatin or karylosis and its 
cytoplasmic membrane rounds up in the late stage (Hirai & Harada, 2004). 
 
1.4.4 Necrosis  
In contrast to apoptosis, necrosis has been traditionally thought to be a positive form 
of cell death (accidental cell death) and initiated by lethal stimuli such as toxic trauma or 
extreme physical damage (Sanz & Tavernarakis, 2005). It is characterized morphologically 
by cytoplasm swelling, destruction of organelles (mitochondrial, endoplasmic reticulum and 
lysosome), disruption of the plasma membrane, leading to the release of intracellular 
components and induces inflammatory responses that affect neighboring cells (Proskuryakov 
et al., 2002; Guimaraes & Linden, 2004). Hence, necrosis is an inadequate means to 
maintain homeostasis, because it can lead to auto-immune reactions (Huettenbrenner et al., 
2003). Necrosis is the term currently used by pathologist to designate the presence of death 
tissues or cells, regardless of the prelethal process (Trump & Berezesky, 1996). Therefore, 
necrosis does not describe a form of cell death, but rather it refers to secondary 
morphological changes to cell death induced by the main mechanisms, including apoptosis 
(Trump & Berezesky, 1996). In the absence of phagocytosis, apoptotic bodies may 
eventually lose their membrane integrity and proceed to secondary necrosis (Bowen et al., 
1998). Nevertheless, there is growing evidence that necrosis by cell death could be 
programmed in nature. The programmed necrosis has been observed only under condition in 
which apoptosis is inhibited either chemically or genetically (Edinger & Thompson, 2004). 
A recent paper by Okada and colleagues has demonstrated that the Abl kinase inhibitor 
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(Gleevec) kills cells not only by activating the apoptotic pathway but also by initiating 
programmed necrosis (Okada et al., 2004). In fact, other studies have highlighted the 
important implications of programmed necrosis in patients treated with alkylating agents 
(Zong et al., 2004) and demonstrated a crucial physiologic role for programmed necrosis in 
response to viral infection (Chan et al., 2003a). 
 
1.4.5 Oncosis 
The term oncosis (from “onkos”, meaning swelling) was first used in 1910 to 
describe ischemic cell death in osteocytes, and recently reintroduced to define the cell death 
distinct from apoptosis (Moore, 2000). Oncosis is characterized as a prelethal phase leading 
to cell death accompanied by cellular swelling, organelles swelling blebbing and an increase 
in the membrane permeability (Boulanger et al., 2004). The process of oncosis ultimately 
interferes the ionic pumps in plasma membrane and depletes the cellular energy stones 
(ATP) (Majno & Joris, 1995). Currently, the translocation of cytosolic phospholipase A2S to 
cellular membrane has been documented to be involved in the hydrolysis of membrane 
phospholipids and decrease the membrane integrity (Ma et al., 2001). Furthermore, cell 
death by oncosis may result in necrosis with karyolysis whereas apoptotic cell death to 
necrosis with karyorrhexis (fragmentation of the cell nucleus) and cell shrinkage (Zhang et 
al., 1998). 
 
1.4.6 Paraptosis 
Paraptosis is another non-apoptotic form of programmed cell death which does not 
involve DNA fragmentation, caspase activation and apoptotic body formation (Sperandio et 
al., 2000). This type of cell death involves extensive cytoplasmic vacuolization, which 
begins with progressive swelling of the mitochondria and endoplasmic reticulum (Wang et 
al., 2004). Paraptotic cell death is distinguished from the apoptosis by its lack of response to 
various caspase inhibitors and Bcl-XL treatment (Chen et al., 2002). However, this 
alternative form of cell death is inhibited by a catalytic mutant of caspase-9 zymogen 
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(Sperandio et al., 2000). There is increasing evidence that paratotic cell death exists in 
parallel with apoptosis, but they may be subjected to different controls (Wyllie & Golstein, 
2001). Similarly, recent study has revealed that both polymorphonuclear leukocytes and 
macrophages are involved in the killing of T9-C2 tumor cells with vacuolization of the 
mitochondria and endoplasmic reticulum (ER) resembling paraptosis (Chen et al., 2002). For 
instance, the overexpression of PDCD5 (an apoptosis-promoting protein) has enhanced 
caspase-independent, paraptosis-like cell death induced by TAJ/TROY (tumor necrosis 
factor receptor protein) in HEK293, Hela and 293 T cells (Wang et al., 2004). 
 
1.4.7 Pyroptosis 
Pyroptosis is a novel form of eukaryotic cell death that is induced by infection with 
Salmonella and Shigella species that inherent proinflammatory (Boise & Collins, 2001; 
Sansonetti et al., 2000). The term pyroptosis from Greek roots “pyro”, relating to fire of 
fever and “ptosis” (to-sis) to denote a falling, to describe pro-inflammatory programmed cell 
death (Cookson & Brennan, 2001). This pathway of cell death is mediated by the activation 
of caspase-1, which clearly distinguishs it from necrosis (Hilbi et al., 1997; Hersh et al., 
1999). Caspase-1 is unique among caspase because it activates the proinflammatory 
cytokines (Fantuzzi & Dinarello, 1999; Monack et al., 2000), but has no autonomous 
function in apoptosis (Li et al., 1995). Subsequently, the proinflammatory pathway is leading 
to cell lysis and release of inflammatory cellular content (Brennan & Cookson, 2000). This is 
an alternative pathway to remove potentially dangerous cells in a development organism, 
like the process that takes the life of Salmonella- infected macrophages (Cookson & 
Brennan, 2001). In addition, the observation caspase-1-dependent during cell death in central 
nervous (Friedlander et al., 1997), immune (Shi et al., 1996) and cardiovascular systems 
(Kolodgie et al., 2000) indicated that pyrotopsis might play a crucial role in variety of 
biological system. 
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1.4.8 Mitotic catastrophe 
The term mitotic catastrophe (mitotic cell death) was first coined by Paul Russell 
and Paul Nurse to describe the lethal fate of Schizosacharomyces pombe cells (Russell & 
Nurse, 1986). More currently, mitotic catastrophe has been used to define the type of 
eukaryotic cell death that is caused by aberrant mitosis (Erenpreisa & Roach, 1999; Ogawa 
et al., 2003). Mitotic catastrophe is characterized by the formation of micronuclei and 
accumulation of karyotypic abnormalities (Chang et al., 1999b). Although mitotic death may 
culminate in features of apoptosis, only apoptotic cell death is induced by wild-type p53 and 
inhibited by Bcl-2 (Merritt et al., 1997; Chang et al., 1999b). Nevertheless, mitotic 
catastrophe occurs in tumor following genotoxic insult or mitotic spindle and is selected as 
an alternative to rapid apoptosis (Erenpreisa et al., 2005). Agents that damage microtubules 
and disrupt the mitotic spindle also cause mitotic catastrophe in the treated-cells (Jordan et 
al., 1996). 
 
1.4.9 Senescence 
Senescence is an irreversible program of cell-cycle arrest that is contributed to the 
deletion of potentially cancerous cells in normal cells (Campisi, 2001). Terminal 
proliferation arrest may result from replicative senescence (Lowe & Lin, 2000). Replicative 
senescence is the progressive erosion of chromosome telomeres, which occurs with each 
cycle of cell division (Wynford, 1999). A senescent cell typically shows cellular changes, 
such as shortening of telomeres, flattened cytoplasm increased granularity and accumulation 
of karyotypic abnormalities (Lowe & Lin, 2000). At the biochemical level, senescence is 
accompanied by changes in metabolism and the induction of SA-β-gal (senescence-
associated β-galactosidase) activity, which commonly used as a marker of senescence in 
human cells (Dimri et al., 1995). The senescence process is initiated by the activation of 
various tumor suppressor genes, including p53, p21, p16 and RB (Lin et al., 1998; Zhu et al., 
1998). Therefore, one of the major roles of the senescence is to inhibit tumor development. 
Recent evidence has demonstrated that anticancer agent (doxorubicin) induced the 
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senescence-like phenotype in human tumor cells (Chang et al., 1999a). Thus, senescence 
may represent a non-apoptotic form of programmed cell death that may provide an important 
determinant of treatment response in tumor cells (Chang et al., 1999a). 
 
1.5 Pathways of apoptotic & non-apoptotic cell death 
Various mechanisms that involve apoptotic and non-apoptotic pathways of cell death 
have been well defined in normal physiology and during tumorigenesis (Okada & Mak, 
2004). Defects in signaling cell death pathways are hallmarks of cancer. A recent study has 
summarized two major apoptotic pathways in mammalian cells: the death receptor induced 
extrinsic pathway and the mitochondria apoptosome mediated apoptotic intrinsic pathways 
(Putcha et al., 2002; Viktorsson et al., 2005). Both of the pathways lead to caspase activation 
and cleavage of cellular substrates (Strasser et al., 2000). At the molecular level, the 
signaling pathways that affect apoptotic sensitivity are activated by engagement of cell 
surface receptors (Rudin & Thompson, 1998; Viktorsson et al., 2005). The largest family of 
cell death receptors are members of tumor necrosis factor (TNF) receptor, including TNF-
R1, Fas (Apo-1/CD95), TRAIL (Apo-2), D3 and D6 (Fulda & Debatin, 2004a) These death 
receptors are characterized by a cytoplasmic domain of 80 amino acids known as the death 
domain, which is essential in transmitting the death signal from the cell’s surface to 
intracellular signaling pathways (Fulda & Debatin, 2004b). 
The extrinsic pathway of apoptosis is triggered by various extracellular stimuli, such 
as UV or γ-irradiation, chemotherapeutic drugs and heat shock (Mor et al., 2002). This 
pathway is initiated by the engagement of death receptors on the cell surface (Kiechle & 
Zhang, 2002). Binding of ligands such as cytokines and TNF to TNFR1 (TNF receptor type 
1), induces the recruitment of adaptor molecules TRADD (TNFR1 associated death domain) 
through association of death domain (Natoli et al., 1998). The TNFR1-TRADD complex 
engages with RIP and TRAF-2 (TNF receptor associated factor 2), leading to NFkB 
activation, which suppress apoptosis activation (Rudin & Thompson, 1998). The recruitment 
of FADD by the TNFR1-TRADD complex resulted in apoptosis through the activation of 
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Caspase-8 (a cell death protease) (Kiechle & Zhang, 2002). Besides the TNF system, Fas and 
TRAIL signaling pathways have been characterized extensively (Hu & Kavanagh, 2003). 
The Fas signaling pathway plays a crucial role in immune surveillance of transformed cells, 
in tissue remodeling and in the removal of self-reactive lymphocytes (Mor et al., 2002). 
TRAIL signaling pathway has attracted interest for cancer therapy because TRAIL seems to 
exert selective toxicity toward cancer cells but not in normal cells (Hu & Kavanagh, 2003). 
Both pathways begin with the ligation of death receptors such as Fas/CD95 or TRAIL 
(TRAIL-R1 & TRAIL-R2) by their cognate ligand (FASL) or agonistic antibodies resulting 
in receptor trimerization and recruitment of adaptor protein FADD via the death domain 
(Fulda & Debatin, 2004b). In turn, FADD binds to other cellular proteins to form the death-
inducing signaling complex (DISC) (Cartee et al., 2003). Once the DISC is assembled, 
proCaspase-8 or proCaspase-10 oligomerization triggers its autoactivation by self-cleavage. 
Following activation, Caspase-8 or Caspase-10 initiates the downstream caspase cascade, 
which eventually ends the apoptosis process (Ghobrial et al., 2005). For the Fas signaling 
pathway, two distinct prototypic cell types have been identified, termed type I and type II 
(Cartee et al., 2003). In type I cells, activation of Caspase-8 is sufficient to directly activate 
downstream effector Caspases and lead in turn to apoptosis (Dai et al., 2003). For type II 
cells, the amount of Caspase-8 generated at the DISC is insufficient to trigger apoptosis and 
the mitochondrial pathway is required for full activation of Caspases (Kim et al., 2002). 
Thus, this pathway involves Bid, which triggers the release of cytochrome c from 
mitochondria in order to translate the death signal (Kim et al., 2002).  
The intrinsic pathway relies on mitochondria as initiators of cell death (Chen et al., 
2004). Various signals converge on mitochondrial, including growth factor withdrawal, 
hypoxia, DNA damage and oncogene induction (Reed & Pellecchia, 2004). The 
mitochondrial pathway is initiated by the proapoptotic protein from the bcl-2 family such as 
Bax, Bak or Bid, which trigger the release of apoptogenic factors such as cytochrome c, 
Smac/DIABLO, Omi/Htr A2 and apoptosis- inducing factor (AIF) (Beere, 2004). Once 
released into the cytosol, cytochrome c binds to an adaptor protein, Apaf-1 (apoptotic 
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protease-activating factor 1) and recruits proCaspase-9 to form the apoptosome complex 
(Beere, 2004). In turn, Caspase-9 is activated and promotes activation of Caspase-3, 
Caspase-6 and Caspase-7, which induce DNA fragmentation and intracellular protein 
degradation (Haupt et al., 2003). Meanwhile, Omi/HtrA2 and Smac/DIABLO are able to 
promote Caspase activation by counteracting to inhibitor of apoptosis protein (IAP) (Okada 
& Mak, 2004).  
Recent studies have identified an association between apoptosis and non-apoptosis 
cell death, especially autophagic cell death (Castro-Obregon, 2002). Both apoptosis and 
autophagy cell death are involved in complementary death pathways in cells (Tanabe et al., 
1999). If Caspase-8 is inhibited during extrinsic signaling pathway, RIP, JNK (Jun N-
terminal kinase) and Atg genes directly activate autophagic cell death (Baehrecke, 2005). 
While active Caspase-8 cleaves RIP and prevents it from activating autophagic cell death 
(Baehrecke, 2005). The autophagy cell death is regulated by the class I and class III 
phosphatidylinositol-3-kinase (PI3K) signaling pathways in animal cells (Yuan et al., 2003). 
Class I PI3K is a negative regulator of autophagy that inhibits autophagosome formation in 
response to insulin-like and other growth factor signals (Levine & Yuan, 2005). Activation 
of class I PI3K leads to the phosphorylation of plasma membrane lipids, which recruit and 
active downstream autophagy inhibitors, including Akt/PKB (protein kinase B), Rhed and 
Tor (Lum et al., 2005). Consequently, inhibition of Tor by rapamyein blocks cell cycle 
progression and thereby results in autophagy (Yoshimori, 2004). By contrast, class III PI3K 
activity is important for early step of autophagic vesicle formation and involves the 
autophagy positive regulator Atg 6 (also known as Beclin 1 in mammalian cells) (Lum et al., 
2005). Autophagic vacuole expansion also involves two ubiquitin-like conjugation pathways 
(the Atg 8 and Atg 12 system) (Ohsumi, 2001). However, the other non-apoptotic signaling 
pathways are not fully understood and remain to be elucidated. 
Further understanding of these diverse signaling pathways, especially the regulations 
of apoptosis and autophagy in response to anticancer therapy, will provide a molecular basis 
in the discovery of novel targeted agents (Ghobrial et al., 2005). Thus, the novel agents may 
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overcome some resistant forms of cancer and may enhance the efficacy of conventional 
chemotherapy regimens. 
 
1.6 Objectives of the present study 
The specific aims of the present study are: 
1. To evaluate the growth inhibitory and cytotoxic properties of some of the locally 
available medicinal plants traditionally used for cancer-related disease, by using a 
variety of cancer cell lines. 
2. To identify the mechanisms of cell death elicited by the most potent plant extract on 
a variety of cancer cell lines. 
3. To elucidate the pattern of apoptotic-related gene expression on different cancer cell 
lines following treatment with the plant extract. 
4. To determine the cytotoxic activity of the fractions from the most potent extract.        
5. To elucidate and determine the cell death mechanism exerted by the potent fractions. 
6. To identify major compounds in the potent fractions.  
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